Emricasan is primarily used in the field of medical research and treatment, particularly for its potential in addressing liver-related conditions. It functions as a caspase inhibitor, targeting pathways involved in apoptosis (programmed cell death) and inflammation. This makes it a promising candidate for treating liver diseases such as non-alcoholic steatohepatitis (NASH), cirrhosis, and acute-on-chronic liver failure. Additionally, it has been explored for its potential to mitigate liver damage caused by hepatitis viruses and other inflammatory liver disorders. Emricasan is also being studied for its role in reducing injury and improving outcomes in organ transplantation, particularly in preventing ischemia-reperfusion injury. Its anti-inflammatory and anti-apoptotic properties are key to its therapeutic applications.